Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
The renin-angiotensin system (RAS) plays a central role in the pathogenesis of preeclampsia. However, drugs targeting the RAS cannot be used during pregnancy due to fetal toxicity. In this study, we utilized an existing drug targeting the RAS system as a lead compound and transformed its structure to create a new compound with a 10-fold increase in safety margin for the fetus.
|